Oncology Committee On Brain Tumor Endpoints Planned For Summer – Pazdur
Executive Summary
FDA's Oncologic Drugs Advisory Committee could meet as soon as summer or early fall to discuss appropriate clinical trial endpoints for primary brain tumors, Office of Oncology Drug Products Director Richard Pazdur said Jan. 27 in an interview with "The Pink Sheet.
You may also be interested in...
Progression-Free Survival Is Meaningful Endpoint For Glioma Trials
Progression free survival assessed at six months should be considered as a meaningful surrogate endpoint in evaluating primary brain tumor clinical trials for accelerated approval, a panel assembled by FDA agreed
Progression-Free Survival Is Meaningful Endpoint For Glioma Trials
Progression free survival assessed at six months should be considered as a meaningful surrogate endpoint in evaluating primary brain tumor clinical trials for accelerated approval, a panel assembled by FDA agreed
Pfizer Oncologic Sutent Will Have Dosing, Slight Price Advantage Over Nexavar
Pfizer's newly approved oncologic Sutent will have a dosing advantage and will be priced at a slight discount compared to Bayer/Onyx' Nexavar